Greetings
Dear colleagues and friends,
Thank you sincerely for visiting the website
of the KASL Alcohol and Metabolic
Liver Disease Study Group.
President, KASL Alcohol and Metabolic Liver Disease Study Group Young Kul Jung
Since its founding in 2009, the KASL Alcohol and Metabolic Liver Disease Study Group has worked to promote systematic research and academic progress in alcohol-related liver disease, and to contribute to the advancement of related fields of medicine through active exchange and collaboration among researchers in Korea and abroad.
Alcohol-related liver disease is now understood not simply as liver injury caused by drinking, but as a complex disease closely linked to diverse pathophysiological mechanisms, including metabolic dysfunction, immunological changes, liver fibrosis and the development of liver cancer. In particular, as interest grows in the shared mechanisms and interactions between alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease (MASLD), an integrated, multidisciplinary approach that spans basic and clinical research is more important than ever.
In step with these changes, our study group will continue to pursue academic activities that broaden our understanding of how alcohol- and metabolism-related liver diseases develop and progress, and that explore new diagnostic and therapeutic strategies.
Through our regular symposia and a variety of academic exchanges, we will also share the latest research findings and clinical experience, and build an open forum where basic researchers and clinicians can share their knowledge and experience and explore new research directions together.
We hope that our newly launched website will serve as a place of communication for sharing the activities and scientific information of the study group, and as a meaningful link that encourages collaboration and joint research among researchers.
With the active participation and interest of our members, the KASL Alcohol and Metabolic Liver Disease Study Group will continue to do its utmost to lead the advancement of research on alcohol- and metabolism-related liver disease and, ultimately, to contribute to better health for patients and a higher quality of care.
We ask for your continued interest and support.
Thank you.
President, KASL Alcohol and Metabolic Liver Disease Study Group Young Kul Jung